Research Comparison
5-Amino-1MQ vs Tirzepatide
A side-by-side research comparison of 5-Amino-1MQ and Tirzepatide drawn from Cobalt Peptides' peptide database records.
5-Amino-1MQ
5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), developed for metabolic and longevity-focused research. By targeting a key regulatory enzyme involved in NAD+ metabolism, it has been investigated for its ability to enhance cellular energy production and mitochondrial efficiency. The compound is primarily explored in the context of metabolic health, body composition, and age-related cellular decline. Preclinical research suggests that modulation of NNMT activity may influence adiposity, insulin sensitivity, and mitochondrial biogenesis, making it of interest in both obesity and longevity research domains.
Tirzepatide
Tirzepatide is a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Engaging both incretin receptors is what distinguishes it from GLP-1-only compounds, and the published literature describes effects on insulin secretion, glucagon suppression and gastric emptying. Licensed medicines containing tirzepatide exist and are prescribed by clinicians; the material supplied here is a research compound and is not one of them.